- Home
- PAX vs HCM Comparison
PAX vs HCM Comparison
Compare PAX & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAX | HCM |
|---|---|---|
| Founded | 1988 | 2000 |
| Country | Cayman Islands | Hong Kong |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.6B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | PAX | HCM |
|---|---|---|
| Price | $16.17 | $13.54 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.75 |
| AVG Volume (30 Days) | ★ 432.1K | 24.9K |
| Earning Date | 11-04-2025 | 08-07-2025 |
| Dividend Yield | ★ 5.40% | N/A |
| EPS Growth | ★ 65.66 | N/A |
| EPS | ★ 0.66 | 0.53 |
| Revenue | $405,792,000.00 | ★ $602,197,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $21.37 | $15.54 |
| P/E Ratio | $24.35 | ★ $5.02 |
| Revenue Growth | ★ 23.46 | N/A |
| 52 Week Low | $9.43 | $11.51 |
| 52 Week High | $16.47 | $19.50 |
Technical Indicators
Market Signals| Indicator | PAX | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 71.86 | 27.75 |
| Support Level | $15.17 | $14.11 |
| Resistance Level | $16.47 | $14.27 |
| Average True Range (ATR) | 0.36 | 0.22 |
| MACD | 0.14 | -0.05 |
| Stochastic Oscillator | 88.66 | 6.78 |
Price Performance
Historical ComparisonAbout PAX Patria Investments Limited
Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.